The FDA-cleared system delivers PTNS for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence.

This decision adds approximately 1.8 million lives to those already covered by other regional Medicare carriers, and makes PTNS treatment coverage available to a total of approximately 31 million Medicare beneficiaries in 35 states.

Uroplasty president and CEO David Kaysen said this Local Coverage Decision by NHIC to cover PTNS treatments further reinforces the strength of their clinical data and support from physicians and provides them the opportunity to expand Urgent PC business in the New England area sooner than they had anticipated.

Minnetonka, Minnesota-based Uroplasty also offers Macroplastique Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency.